Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetes
Uložené v:
| Názov: | Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetes |
|---|---|
| Autori: | Christian Seerup Frandsen, Thomas F. Dejgaard, Ali Asmar, Lise Tarnow, Nanna B. Johansen, Sten Madsbad, Filip K. Knop, Henrik U. Andersen |
| Zdroj: | Dejgaard, T F, Johansen, N B, Frandsen, C S, Asmar, A, Tarnow, L, Knop, F K, Madsbad, S & Andersen, H U 2017, ' Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetes ', Diabetes, Obesity and Metabolism Online, vol. 19, no. 5, pp. 734-738 . https://doi.org/10.1111/dom.12841 |
| Informácie o vydavateľovi: | Wiley, 2017. |
| Rok vydania: | 2017 |
| Predmety: | Male, type 1 diabetes, Diabetic Cardiomyopathies, Denmark, Drug Resistance, Blood Pressure, Carotid Intima-Media Thickness, Overweight/complications, Glycated Hemoglobin A/analysis, Hypoglycemic Agents/adverse effects, Body Mass Index, DOUBLE-BLIND, 0302 clinical medicine, cardiovascular disease, Risk Factors, Heart Rate, GLYCEMIC CONTROL, Liraglutide/adverse effects, Insulin, GLP-1 analogue, 2. Zero hunger, liraglutide, GLUCAGON-LIKE PEPTIDE-1, Diabetic Cardiomyopathies/diagnostic imaging, Heart Rate/drug effects, clinical trial, Middle Aged, INSULIN, 3. Good health, Drug Therapy, Combination/adverse effects, Cardiovascular Diseases, Insulin/therapeutic use, TRIAL, PARALLEL, Drug Therapy, Combination, Female, Adult, Cardiovascular Diseases/complications, Pulse Wave Analysis, Blood Pressure/drug effects, 03 medical and health sciences, Double-Blind Method, Journal Article, Humans, Hypoglycemic Agents, Glycated Hemoglobin, Diabetic Angiopathies/diagnostic imaging, Diabetes Mellitus, Type 1/blood, Liraglutide, Denmark/epidemiology, Diabetes Mellitus, Type 1, Diabetic Angiopathies |
| Popis: | We investigated the short‐term effect of adding liraglutide 1.8 mg once daily to insulin treatment on cardiovascular risk factors in patients with type 1 diabetes. In total, 100 overweight (BMI ≥25 kg/m2) adult patients (age ≥18 years) with type 1 diabetes and HbA1c ≥ 8% (64 mmol/mol) were randomized to liraglutide 1.8 mg or placebo added to insulin treatment in a 24‐week double‐blinded, placebo‐controlled trial. At baseline and after 24 weeks of treatment, 24‐hour blood pressure and heart rate, pulse pressure, pulse wave velocity and carotid intima‐media thickness were evaluated. Compared with placebo, liraglutide increased 24‐hour heart rate by 4.6 beats per minute (BPM); P = .0015, daytime heart rate by 3.7; P = .0240 and night‐time heart rate by 7.5 BPM; P mm Hg; P = .0362 in the liraglutide group compared with placebo. In conclusion, in patients with long‐standing type 1 diabetes, liraglutide as add‐on to insulin increased heart rate and did not improve other cardiovascular risk factors after 24 weeks of treatment. |
| Druh dokumentu: | Article |
| Jazyk: | English |
| ISSN: | 1463-1326 1462-8902 |
| DOI: | 10.1111/dom.12841 |
| Prístupová URL adresa: | https://pubmed.ncbi.nlm.nih.gov/27935240 https://www.infona.pl/resource/bwmeta1.element.wiley-dom-v-19-i-5-dom12841 https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.12841 https://www.ncbi.nlm.nih.gov/pubmed/27935240 https://onlinelibrary.wiley.com/doi/abs/10.1111/dom.12841 https://pubmed.ncbi.nlm.nih.gov/27935240/ https://pure-portal.regsj.dk/da/publications/effects-of-liraglutide-on-cardiovascular-risk-factors-in-patients |
| Rights: | Wiley Online Library User Agreement |
| Prístupové číslo: | edsair.doi.dedup.....3d5ef37c88dd7ab056d26b3259e8edf3 |
| Databáza: | OpenAIRE |
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstrakt: | We investigated the short‐term effect of adding liraglutide 1.8 mg once daily to insulin treatment on cardiovascular risk factors in patients with type 1 diabetes. In total, 100 overweight (BMI ≥25 kg/m2) adult patients (age ≥18 years) with type 1 diabetes and HbA1c ≥ 8% (64 mmol/mol) were randomized to liraglutide 1.8 mg or placebo added to insulin treatment in a 24‐week double‐blinded, placebo‐controlled trial. At baseline and after 24 weeks of treatment, 24‐hour blood pressure and heart rate, pulse pressure, pulse wave velocity and carotid intima‐media thickness were evaluated. Compared with placebo, liraglutide increased 24‐hour heart rate by 4.6 beats per minute (BPM); P = .0015, daytime heart rate by 3.7; P = .0240 and night‐time heart rate by 7.5 BPM; P mm Hg; P = .0362 in the liraglutide group compared with placebo. In conclusion, in patients with long‐standing type 1 diabetes, liraglutide as add‐on to insulin increased heart rate and did not improve other cardiovascular risk factors after 24 weeks of treatment. |
|---|---|
| ISSN: | 14631326 14628902 |
| DOI: | 10.1111/dom.12841 |